Related Experiment Video
Updated: Aug 8, 2026
05:32
Embryo Microinjection for Transgenesis in Drosophila
Published on: June 7, 2024
Phi c31 integrase induces chromosomal aberrations in primary human fibroblasts
1Kennedy Institute-National Eye Clinic, Glostrup, Denmark.
Gene Therapy
|May 5, 2006
Summary
The phiC31 integrase enzyme, explored for gene therapy, was found to cause numerous chromosomal abnormalities in human cells. This suggests the integrase enzyme may act as a mutagen, posing risks for gene therapy applications.
Area of Science:
- Molecular Biology
- Genetics
- Gene Therapy
Background:
- Nonviral gene therapy seeks efficient and safe methods for introducing genetic material into cells.
- Site-specific integration into the host genome is a desirable feature for stable gene expression and therapeutic outcomes.
- The phiC31 integrase enzyme offers potential for directed chromosomal integration.
Purpose of the Study:
- To investigate the effects of phiC31 integrase expression on the chromosomal stability of normal human cells.
- To assess the mutagenic potential of the phiC31 integrase enzyme in a cellular context.
Main Methods:
- Generation of stably transfected primary human fibroblasts expressing phiC31 integrase.
- Cytogenetic analysis of transfected cells and control cells.
- Evaluation of chromosomal abnormalities, including translocations.
Main Results:
- Cells expressing phiC31 integrase exhibited numerous chromosomal abnormalities.
- Various translocations were identified in cells with integrase expression.
- Control cells remained cytogenetically normal.
Conclusions:
- PhiC31 integrase expression in human fibroblasts leads to significant chromosomal instability.
- The phiC31 integrase enzyme demonstrates mutagenic properties.
- Further research is needed to address the safety concerns of phiC31 integrase for gene therapy applications.
